Global Metabolism Assays Market Insights Forecasts to 2033

• The Global Metabolism Assays Market Size was Valued at USD 1.35 Billion in 2023
• The Market Size is Growing at a CAGR of 7.10% from 2023 to 2033
• The Worldwide Metabolism Assays Market Size is Expected to Reach USD 2.68 Billion by 2033
• Asia Pacific is Expected to Grow the fastest during the forecast period.

The Global Metabolism Assays Market Size is Anticipated to Exceed USD 2.68 Billion by 2033, Growing at a CAGR of 7.10% from 2023 to 2033.

Market Overview

Metabolism assays are analytical methods that quantitatively determine the activity of metabolites or cellular processes, providing valuable insights into metabolic reactions and the mechanisms of action of biomolecules such as carbohydrates and proteins. Its primary purpose is to understand the metabolic pathway/phenotype changes in research. The metabolic assay is used to identify metabolic stability in chemical structures in connection with hepatic metabolism by evaluating the rate of clearance of a drug using the liver hepatocytes or microsomes. It also offers critical insights into the pharmacokinetics and pharmacodynamics properties of drugs, aiding in selecting drug candidates with optimal metabolic characteristics. Personalized medicine and the incorporation of artificial intelligence and machine learning in metabolic research are poised to offer lucrative opportunities for market expansion. For instance, the development of the use of 2-deoxy-d-[14C]glucose (DG), a glucose analog, as a tracer to determine local rates of glucose utilization in the brain in vivo is the major advancement in metabolic assays.

Report Coverage

This research report categorizes the market for the global metabolism assays market based on various segments and regions forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the global metabolism assays market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the global metabolism assays market.

Driving Factors

The growing prevalence of chronic diseases such as obesity, diabetes, and mitochondrial diseases surges the need for deeper insights and breakthrough treatments for patients that ultimately resulted in driving the global metabolism assay market. The increasing research & development related to metabolic disorders for novel drug discovery and development by the pharmaceutical industries are significantly contributing to propelling the market growth for metabolism assay. Innovative technologies such as high throughput screening and bioinformatics are integrated for drug discovery and the growing demand for personalized medical treatments (tailored medical treatments). Further, the demand for in-depth metabolic profiling for identifying and quantifying specific endogenous metabolites, which is useful in clinical diagnostic settings, and in the field of drug characterization bolstering the market demand. The Increase in funding and investments in metabolic research are majorly contributing to market growth.

Restraining Factors

The high cost of metabolic assay analyzers and the limited budget facilities like smaller research labs or healthcare facilities are impeding the global metabolism assays market. The presence of alternative methods and techniques is restraining the global metabolism assays market.

Market Segmentation

The global metabolism assays market share is classified into technology, product type, application, and end-use.

• The colorimetry segment is expected to hold the largest share of the global metabolism assays market during the forecast period.   

Based on the technology, the global metabolism assays market is categorized into colorimetry, spectrometry, and fluorimetry. Among these, the colorimetry segment is expected to hold the largest share of the global metabolism assays market during the forecast period. Colorimetry assay results are quantitatively and semiquantitatively identified by the naked eyes. The versatility of colorimetry assay enables its widespread application in metabolic research owing to its affordability as well as, widespread adoption. The ongoing advancements including the development of novel substrates, enzyme-linked reactions, and detection methods driving the market demand.

• The kits, reagents & consumables segment dominated the market with the largest revenue share in 2023.

Based on the product type, the global metabolism assays market is categorized into kits, reagents & consumables, instruments & accessories, and software & services. Among these, the kits, reagents & consumables segment dominated the market with the largest revenue share in 2023. Kits, reagents, and consumables provide ready-to-use components to the researchers for performing various metabolic assays, possessing accuracy, rapid response, ease-of-use (with standard protocols), and low costs. Versatile tools are used by researchers to study glucose metabolism, lipid metabolism, enzymatic activities and other metabolic processes.  

• The diabetes segment dominates the global metabolism assays market during the forecast period.

Based on the application, the global metabolism assays market is categorized into diabetes, obesity, cancer, and others. Among these, the diabetes segment dominates the global metabolism assays market during the forecast period. Metabolic assay facilitates the assessment of various metabolic parameters involved in the disease’s pathophysiology. It enables the measurement of insulin sensitivity, glucose metabolism, and pancreatic beta-cell function, offering valuable information about its etiology and progression. The rising prevalence of diabetes increasing the demand for metabolism assays for diabetic research and clinical use.

• The hospitals segment is anticipated to hold the largest market share over the forecast period.

Based on the end-use, the global metabolism assays market is categorized into hospitals, diagnostic laboratories, pharmaceutical & biopharmaceutical companies, and others. Among these, the hospitals segment is anticipated to hold the largest market share over the forecast period. To identify and monitor metabolic disorders such as diabetes, lipid disorder, and metabolic syndrome in hospitals for diagnostics. Metabolism assays provide insights to healthcare professionals to personalize treatment plans. The clinical and research application of metabolic assay in the hospital segment and the rising demand for precision medicine and evidence-based care are bolstering the market demand for metabolism assays.

Regional Segment Analysis of the Global Metabolism Assays Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

North America is anticipated to hold the largest share of the global metabolism assays market over the predicted timeframe.

North America is projected to hold the largest share of the global metabolism assays market over the forecast period. The increasing prevalence of chronic diseases in the region. Government initiatives and technological advancements are contributing to market growth for metabolism assays. Further, the presence of hospitals, diagnostic and research institutes for the development of novel precision medicine, and evidence-based clinical treatment are significantly driving the market. The growing cases of metabolic disorders in the region are anticipated to surge the market demand. Furthermore, the rise in awareness about metabolic disorders surges the demand for advanced diagnostic and treatment modalities which in turn drives the market demand in the region

Asia-Pacific is expected to grow at the fastest CAGR growth of the global metabolism assays market during the forecast period.  The presence of well-established pharmaceutical and biotechnology organizations is propelling the market for metabolic assays. The increasing awareness about metabolic disorders and their treatment with the growing prevalence of chronic diseases such as diabetes, cardiovascular disorder, and obesity surges the market demand for metabolism assays. Further, rapid urbanization and lifestyle changes such as sedentary lifestyles, unhealthy diets, and obesity which are responsible for the growing prevalence of metabolic disorders are driving the market demand in the region.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the global metabolism assays market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Merck KGaA
• Thermo Fisher Scientific, Inc.
• Agilent Technologies, Inc.
• Abcam Plc.
• Promega Corporation
• Bio-Rad Laboratories
• RayBiotech Life, Inc.
• BMG Labtech GmbH
• Kaneka Eurogentic S.A
• Becton, Dickinson and Company
• PerkinElmer Inc.
• Enzo Biochem, Inc.
• Promega Corporation
• Sartorius AG
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Developments

• In September 2023, Agilent Technologies Inc. signed a Memorandum of Understanding (MoU) with the Advanced Cell Therapy and Research Institute, Singapore (ACTRIS), to develop cell and gene therapy advancement over the next three years. The new partnership sets out to install and operate Agilent’s xCELLigence real-time cell analyzer, Seahorse XF technology, and other cell analysis portfolio in Singapore’s largest national cell and gene therapy process development and manufacturing facility at ACTRIS. The partnership also enables early access to Agilent’s new cell analysis platform which may be fundamental in developing cellular therapies for marketing authorization.

• In March 2022, Thermo Fisher Scientific, the world leader in serving science, and Symphogen, an affiliate of and the antibody center of excellence within the international pharmaceutical company Servier, announced the continuation of their collaboration to provide biopharmaceutical discovery and development laboratories with innovative tools and streamlined workflows for efficient characterization of complex therapeutic proteins.

• In August 2021, Abcam plc, a global leader in the supply of life science research tools, announced that it has entered into a definitive agreement to acquire BioVision, Inc., a wholly owned subsidiary of Boai NKY Medical Holdings Ltd. (“NKY”), for $340 million. It is expected to bring greater control over the innovation and distribution of BioVision’s product portfolio and create value through portfolio expansion and leveraging Abcam’s global channels to market.

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2033. Spherical Insights has segmented the global metabolism assays market based on the below-mentioned segments: 

Global Metabolism Assays Market, By Technology

• Colorimetry
• Spectrometry
• Fluorimetry

Global Metabolism Assays Market, By Product Type

• Kits, Reagents & Consumables
• Instruments & Accessories
• Software & Services

Global Metabolism Assays Market, By Application

• Diabetes
• Obesity
• Cancer
• Others

Global Metabolism Assays Market, By End-Use

• Hospitals
• Diagnostic Laboratories
• Pharmaceutical & Biopharmaceutical Companies
• Others

Global Metabolism Assays Market, Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • Uk
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa